Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
340
Trial Sponsor
Clinical Trial Start Date
2011
0Primary Completion Date
June 20, 2017
0Study Completion Date
June 20, 2017
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma0
Last Updated
February 5, 2018
0Masking Type
None (Open Label)0
Study summary
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Olaparib may help temozolomide kill more tumor cells by making tumor cells more sensitive to the drug. PURPOSE: This phase I trial is studying the side effects and best dose of olaparib and temozolomide in treating patients with relapsed glioblastoma.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
